BiovaxID(TM), Personalized Anti-Cancer Vaccine From Biovest International, Inc., Produces Long Term Clinical Remission And 95 Percent Overall Survival In Patients With Follicular Non-Hodgkin's Lymphoma In Phase 2 Clinical Trial

TAMPA, Fla.--(BUSINESS WIRE)--Jan. 10, 2006-- Tumor-Free Survival from Investigational Vaccine Compares Favorably with Published Reports of Chemotherapy Alone, and Regimens That Include Rituxan(R)(1) While There is No Consensus as to What Constitutes a "Cure" of Non-Hodgkin's Lymphoma, Phase 2 Results Are Encouraging. Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), and its subsidiary, Biovest International, Inc. (OTCBB:BVTI), jointly reported long-term follow-up data from its Phase 2 clinical trial of BiovaxID(TM), a personalized vaccine for follicular lymphoma, during a poster session at the 47th Annual Meeting of the American Society of Hematology in Atlanta, December 11, 2005 . (Abstract #2441)